Saul J. Priceman discovered that recombinant oncolytic poxviruses containing truncated CD19 (CD19t), a tumor-specific antigen, can promote the labeling of tumor cells by viral infection, leading to improved targeting of CAR-T cells. The gene discussed is CD19; the disease is neoplasm.